神经分泌生物科学 NBIX 深 沪
等待开盘 02-13 09:30:00 美东时间
123.10
-14.300
-10.41%
华盛通- 最 高148.56
- 今 开132.34
- 成交量 415.67万股
- 最 低 122.1375
- 昨 收 137.40
- 总市值 1176.55万
- 52周最高 160.18
- 市盈率 静 134.51
- 换手率 4349.04%
- 52周最低 84.23
- 委 比 -71.61%
- 总股本 9.56万
- 历史最高 160.18
- 量 比 4.01
- 振 幅 19.23%
- 历史最低 1.10
- 每 手 1
- 风险率 14.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Preview: Neurocrine Biosciences's Earnings
Neurocrine Biosciences (NASDAQ:NBIX) is gearing up to announce its quarterly ea...
02-11 00:01
Neurocrine BiosciencesInitiates Phase 2 Clinical Study Evaluating NBI-1065890
This Phase 2, randomized, double-blind, placebo-controlled study will enroll approximately 100 adult subjects with TD and will assess the efficacy, safety, and tolerability of NBI-1065890 compared with placebo. The
01-26 21:38
Neurocrine Biosciences Presents Head-to-Head INGREZZA Capsules Data
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatmentVMAT2 occupancy is a key measurement thought
01-15 21:36
Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
01-06 00:00
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
2025-11-12 01:51
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
Neurocrine Biosciences Provides Update on ERUDITE™Phase 2 Data For Luvadaxistat
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition Measures Across Population
2024-09-13 04:11
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
During the last three months, 19 analysts shared their evaluations of Neurocrin...
2024-09-09 23:01
Barclays Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $160
Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $180 to $160.
2024-09-09 21:41
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences.
2024-09-09 01:05
